Transgene. 

Transgene S.A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses. Its core mission is to develop innovative treatments for both cancer and various infectious diseases. The company's drug development pipeline includes several promising candidates: TG4050, a therapeutic vaccine, is currently in early-stage Phase I clinical trials for its potential use against ovarian cancer and certain types of HPV-negative head and neck cancers. TG4001, another therapeutic vaccine, has progressed to Phase II clinical trials, where it is being evaluated for the treatment of HPV-positive cancers. TG6002, an oncolytic virus, is undergoing Phase I/IIa clinical development, targeting a diverse range of solid tumors, specifically gastrointestinal adenocarcinomas affecting the stomach, pancreas, and colon. BT-001, also an oncolytic virus, is in Phase I/II clinical trials for various solid tumor indications. Beyond these, Transgene's portfolio also features TG1050, a therapeutic vaccine aimed at chronic hepatitis B, and Pexa-Vec, an oncolytic virus designed to address solid tumors. To bolster its research and development efforts, Transgene has established key strategic partnerships with prominent pharmaceutical companies including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation. Furthermore, it holds licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and maintains additional collaborations with Sanofi, BioInvent, and Randox. Founded in 1979, Transgene S.A. is based in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.